LTRNHealthcare · BiotechnologyThe 2 Wall Street analysts covering Lantern Pharma, Inc. hold a median 12-month price target of $18 — +641.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Lantern Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LTRN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +641.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Apr 2025 | Lake Street | Initiates | Buy | — |
| 2 Apr 2025 | Lake Street | Initiates | Buy | $25 |
| 25 Apr 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 10 Aug 2023 | EF Hutton | Reiterates | Buy | — |
| 26 June 2023 | EF Hutton | Maintains | Buy | — |
| 25 May 2023 | EF Hutton | Assumes | Buy | $11 |
| 18 May 2023 | HC Wainwright & Co. | Initiates | Neutral | — |
| 21 Mar 2023 | EF Hutton | Reiterates | Buy | — |
| 15 Feb 2023 | EF Hutton | Maintains | Buy | — |
| 1 Nov 2022 | EF Hutton | Initiates | Buy | — |
| 11 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Oct 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 28 July 2020 | Colliers Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LTRN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 14% of US stocks
Cheaper than 68% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lantern Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lantern Pharma Inc. (LTRN) held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The excerpt provides the headline and source information for the earnings call transcript.
Why it matters — LTRN watchers would care because the earnings call transcript is a key source of detail on the company's quarterly results and management commentary.
Lantern Pharma reported its second quarter 2026 financial results and provided a business update, as announced by the company. The release presents the company's quarterly financial figures alongside an update on its operations.
Why it matters — LTRN watchers would care because the quarterly financial results and business update offer the latest official information on the company's financial performance and strategic progress.
Lantern Pharma announced it will report its second quarter 2026 operating and financial results on August 14th, 2026 at 9:00 a.m. ET, according to a Business Wire release.
Why it matters — LTRN watchers can mark the calendar for the upcoming earnings report, which will provide updates on the company's quarterly operating and financial performance.
Lantern Pharma (Nasdaq: LTRN) launched Open-Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform for the transformation of medicine. The new entity was established through a separation from Lantern Pharma, according to the announcement.
Why it matters — LTRN watchers would care because the company is expanding and commercializing its AI platform through a newly formed separate entity, which broadens the reach of its technology.
Lantern Pharma is advancing its EMA-cleared Phase 1b/2 clinical trial of LP-184 (Zirdafulven) for biomarker-selected advanced bladder cancer.
Why it matters — This trial advancement signals that Lantern Pharma is progressing LP-184, a key pipeline candidate, into a later-stage study for a specific cancer population in a major regulatory region.
The 2 Wall Street analysts covering Lantern Pharma, Inc. have a median 12-month price target of $18, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Lantern Pharma, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lantern Pharma, Inc. 56 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Lantern Pharma, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +641.5% from the last close, and Ticker Nerd's factor model ranks Lantern Pharma, Inc. 56 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lantern Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.
Lantern Pharma, Inc. returned -43.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Lantern Pharma Inc. is a clinical-stage biotechnology company specializing in oncology drug discovery and development through artificial intelligence, machine learning, and genomics.
The most recent item we track (Seeking Alpha, 14 Aug 2026): "Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript". Lantern Pharma Inc. (LTRN) held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The excerpt provides the headline and source information for the earnings call transcript.
Lantern Pharma Inc. is a clinical-stage biotechnology company specializing in oncology drug discovery and development through artificial intelligence, machine learning, and genomics. At its core is the proprietary RADR platform, which analyzes hundreds of billions of oncology-focused data points and over 200 advanced machine learning algorithms to identify biomarkers, predict drug responses, design clinical trials, and accelerate the development of precision cancer therapies for solid tumors and blood cancers. The company's pipeline features lead candidates such as LP-300 in phase 2 trials for non-small cell lung cancer in never-smokers, LP-184 in phase 1 for solid tumors including pancreatic, breast, bladder, lung, glioblastoma, and other CNS cancers, and LP-284 in phase 1 for non-Hodgkin’s lymphomas like mantle cell and double hit lymphoma, alongside an ADC program spanning 12 cancer indications. Lantern Pharma Inc. focuses on stratifying patients into responders and non-responders to de-risk trials, develop companion diagnostics, and target genetically defined subsets with high unmet needs. Founded in 2013 and headquartered in Dallas, Texas, it operates at the intersection of AI and precision oncology to transform drug development processes.
CEO Mr. Panna Sharma · 16 employees · United States · https://www.lanternpharma.com